Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Conditions
Interventions
Oral Azacitidine
Placebo
+1 more
Locations
196
United States
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States
Tower Hematology/Oncology Medical Group and Tower Cancer Research Found
Beverly Hills, California, United States
City Of Hope
Duarte, California, United States
California Cancer Associates for Research and Excellence cCARE
Escondido, California, United States
Marin Oncology Associates
Greenbrae, California, United States
UCSD-Thornton Hospital
La Jolla, California, United States
Start Date
April 26, 2013
Primary Completion Date
January 25, 2019
Completion Date
December 21, 2023
Last Updated
January 7, 2025
NCT06303193
NCT05564390
NCT06847867
NCT05969860
NCT07216443
NCT05588154
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions